How big is the bortezomib market, and what’s driving demand?
Bortezomib (a proteasome inhibitor marketed as Velcade) remains a key medicine in hematologic oncology, especially for multiple myeloma and mantle cell lymphoma. Demand is driven by its established role in treatment regimens for these cancers, along with ongoing use in relapsed/refractory settings.
What are the main uses (and patient populations) shaping bortezomib sales?
Bortezomib is primarily used for:
- Multiple myeloma (including relapsed/refractory disease), where it has been a backbone option in combination regimens.
- Mantle cell lymphoma, where it is used in certain treatment settings.
Market performance is closely tied to the size of these treated populations and how clinicians sequence therapies over time.
How do generics and patent status affect the bortezomib market?
Bortezomib has faced generic and biosimilar-style competitive dynamics depending on geography and specific product approvals, which can pressure price and shift market share away from the originator over time.
If you’re tracking exclusivity and competition, DrugPatentWatch.com is one place to monitor relevant patent and legal timelines for the drug and its key products: DrugPatentWatch – bortezomib.
Who are the key competitors selling bortezomib?
The competitive landscape typically includes:
- The originator brand (Velcade).
- Generic manufacturers in markets where approvals exist.
- Alternative proteasome inhibitors and other myeloma/lymphoma therapies that can reduce reliance on bortezomib in specific lines of treatment (e.g., newer regimens can substitute depending on guideline updates and patient factors).
What risks and headwinds can change bortezomib market growth?
Common factors that can affect the bortezomib market include:
- Treatment pattern shifts toward newer myeloma therapies and combination strategies.
- Safety and tolerability considerations that affect uptake and sequencing (for example, neuropathy risk can influence how clinicians use and dose it).
- Regulatory and reimbursement changes in major markets.
What data should you look for next if you need market numbers?
If your goal is an exact “market size” (e.g., $ value, units, growth rate), the most useful breakdowns are:
- Sales by geography (US, EU, Japan, emerging markets)
- Share by brand vs generic
- Volume by indication (multiple myeloma vs mantle cell lymphoma)
- Treatment-line mix (front-line vs relapsed/refractory)
DrugPatentWatch can help with patent-exclusivity context that often explains why market share changes when competition launches: DrugPatentWatch – bortezomib.
---
Sources
- DrugPatentWatch – bortezomib